Firstly, a study conducted by Duffy and colleagues tested the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody tremelimumab plus TACE in 32 BCLC stage B HCC patients [63]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.